A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice

PLoS ONE

Volumn 5, Issue 7, 2010, Pages 1-15

  Kurz, Alexander ^a   Double, Kay L ^b   Lastres Becker, Isabel ^a,k   Tozzi, Alessandro ^c,j   Tantucci, Michela ^c   Bockhart, Vanessa ^d   Bonin, Michael ^e   García Arencibia, Moisés ^f   Nuber, Silke ^e   Schlaudraff, Falk ^g   Liss, Birgit ^g   Fernández Ruiz, Javier ^f   Gerlach, Manfred ^h   Wullner, Ullrich ⁱ   Lüddens, Hartmut ^d   Calabresi, Paolo ^c,j   Auburger, Georg ^a   Gispert, Suzana ^a  

^a GOETHE UNIVERSITY MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF PERUGIA   (Italy)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e UNIVERSITY OF TÜBINGEN   (Germany)

^f SCHOOL OF MEDICINE   (Spain)

^g UNIVERSITY OF ULM   (Germany)

^h UNIVERSITY OF WÜRZBURG   (Germany)

ⁱ UNIVERSITY OF BONN   (Germany)

^j EUROPEAN BRAIN RESEARCH INSTITUTE   (Italy)

^k CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; ALPHA SYNUCLEIN; CANNABINOID 1 RECEPTOR; CATECHOL METHYLTRANSFERASE; DOPAMINE; PHOSPHODIESTERASE VII; PHOSPHODIESTERASE VIIB; PROTEIN HOMER 1; UNCLASSIFIED DRUG; ATF2 PROTEIN, MOUSE; CARRIER PROTEIN; FREQUENIN CALCIUM SENSOR PROTEINS; NEURONAL CALCIUM SENSOR; NEUROPEPTIDE; PDE7B PROTEIN, MOUSE; PROTEIN HOMER;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC TRANSMISSION; DOWN REGULATION; ENZYME DEGRADATION; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; LONG TERM DEPRESSION; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; AGING; ANIMAL; DNA MICROARRAY; ELECTROPHYSIOLOGY; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; MOUSE MUTANT; PHYSIOLOGY; RADIOIMMUNOPRECIPITATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ACTIVATING TRANSCRIPTION FACTOR 2; AGING; ALPHA-SYNUCLEIN; ANIMALS; CARRIER PROTEINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 7; DOPAMINE; ELECTROPHYSIOLOGY; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MICE; MICE, KNOCKOUT; MICE, MUTANT STRAINS; NEURONAL CALCIUM-SENSOR PROTEINS; NEURONAL PLASTICITY; NEUROPEPTIDES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RADIOIMMUNOPRECIPITATION ASSAY; RECEPTOR, CANNABINOID, CB1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77955347330     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011464     Document Type: Article

References (57)

1. Chandra S, Gallardo G, Fernandez-Chacon R, Schluter OM, Sudhof TC (2005) Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 123: 383-396.
2. Liu S, Ninan I, Antonova I, Battaglia F, Trinchese F, et al. (2004) alpha-Synuclein produces a long-lasting increase in neurotransmitter release. Embo J 23: 4506-4516.
3. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047.
4. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, et al. (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science 302: 841.
5. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M (1998) alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci U S A 95: 6469-6473.
6. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, et al. (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24: 197-211.
7. Krasnova IN, Betts ES, Dada A, Jefferson A, Ladenheim B, et al. (2007) Neonatal dopamine depletion induces changes in morphogenesis and gene expression in the developing cortex. Neurotox Res 11: 107-130.
8. Seeman P, Niznik HB (1990) Dopamine receptors and transporters in Parkinson's disease and schizophrenia. Faseb J4: 2737-2744.
9. Gerfen CR (2000) Molecular effects of dopamine on striatal-projection pathways. Trends Neurosci 23: S64-70.
10. Calabresi P, Mercuri NB, Di Filippo M (2009) Synaptic plasticity, dopamine and Parkinson's disease: one step ahead. Brain 132: 285-287.
11. Day M, Wang Z, Ding J, An X, Ingham CA, et al. (2006) Selective elimination ofglutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat Neurosci 9: 251-259.
12. Cenci MA, Lundblad M (2006) Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia. J Neurochem 99: 381-392.
13. Gispert S, Del Turco D, Garrett L, Chen A, Bernard DJ, et al. (2003) Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation. Mol Cell Neurosci 24: 419-429.
14. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, et al. (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287: 1265-1269.
15. Richfield EK, Thiruchelvam MJ, Cory-Slechta DA, Wuertzer C, Gainetdinov RR, et al. (2002) Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Exp Neurol 175: 35-48.
16. Tofaris GK, Garcia Reitbock P, Humby T, Lambourne SL, O'Connell M, et al. (2006) Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders. J Neurosci 26: 3942-3950.
17. Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, et al. (2000) Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25: 239-252.
18. Chandra S, Fornai F, Kwon HB, Yazdani U, Atasoy D, et al. (2004) Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions. Proc Natl Acad Sci U S A 101: 14966-14971.
19. Al-Wandi A, Ninkina N, Millership S, Williamson SJ, Jones PA, et al. (2008) Absence of alpha-synuclein affects dopamine metabolism and synaptic markers in the striatum of aging mice. Neurobiol Aging.
20. Lotharius J, Barg S, Wiekop P, Lundberg C, Raymon HK, et al. (2002) Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line. J Biol Chem 277: 38884-38894.
21. Sidhu A, Wersinger C, Vernier P (2004) alpha-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease. FEBS Lett 565: 1-5.
22. Thomas U (2002) Modulation of synaptic signalling complexes by Homer proteins. J Neurochem 81: 407-413.
23. Kreitzer AC, Malenka RC (2007) Endocannabinoid-mediated rescue ofstriatal LTD and motor deficits in Parkinson's disease models. Nature 445: 643-647.
24. Giuffrida A, Parsons LH, Kerr TM, Rodriguez de Fonseca F, Navarro M, et al. (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2: 358-363.
25. Zeng BY, Dass B, Owen A, Rose S, Cannizzaro C, et al. (1999) Chronic L-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats. Neurosci Lett 276: 71-74.
26. Calabresi P, Ascone CM, Centonze D, Pisani A, Sancesario G, et al. (1997) Opposite membrane potential changes induced by glucose deprivation in striatal spiny neurons and in large aspiny interneurons. J Neurosci 17: 1940-1949.
27. Calabresi P, Mercuri NB, Bernardi G (1990) Synaptic and intrinsic control of membrane excitability of neostriatal neurons. II. An in vitro analysis. J Neurophysiol 63: 663-675.
28. Jiang ZG, North RA (1991) Membrane properties and synaptic responses ofrat striatal neurones in vitro. J Physiol 443: 533-553.
29. Kita H, Kitai ST (1994) The morphology ofglobus pallidus projection neurons in the rat: an intracellular staining study. Brain Res 636: 308-319.
30. Calabresi P, Picconi B, Tozzi A, Di Filippo M (2007) Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci 30: 211-219.
31. Kitada T, Tong Y, Gautier CA, Shen J (2009) Absence of nigral degeneration in aged parkin/DJ-1/PINK1 triple knockout mice. J Neurochem 111: 696-702.
32. Itier JM, Ibanez P, Mena MA, Abbas N, Cohen-Salmon C, et al. (2003) Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum Mol Genet 12: 2277-2291.
33. Lotharius J, Brundin P (2002) Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. Hum Mol Genet 11: 2395-2407.
34. Mosharov EV, Staal RG, Bove J, Prou D, Hananiya A, et al. (2006) Alpha-synuclein overexpression increases cytosolic catecholamine concentration. J Neurosci 26: 9304-9311.
35. Wersinger C, Sidhu A (2005) Disruption of the interaction of alpha-synuclein with microtubules enhances cell surface recruitment of the dopamine transporter. Biochemistry 44: 13612-13624.
36. Senior SL, Ninkina N, Deacon R, Bannerman D, Buchman VL, et al. (2008) Increased striatal dopamine release and hyperdopaminergic-like behaviour in mice lacking both alpha-synuclein and gamma-synuclein. Eur J Neurosci 27: 947-957.
37. Tappe A, Kuner R (2006) Regulation of motor performance and striatal function by synaptic scaffolding proteins of the Homer1 family. Proc Natl Acad Sci U S A 103: 774-779.
38. Henning J, Koczan D, Glass A, Karopka T, Pahnke J, et al. (2007) Deep brain stimulation in a rat model modulates TH, CaMKIIa and Homer1 gene expression. Eur J Neurosci 25: 239-250.
39. Yamada H, Kuroki T, Nakahara T, Hashimoto K, Tsutsumi T, et al. (2007) The dopamine D1 receptor agonist, but not the D2 receptor agonist, induces gene expression of Homer 1a in rat striatum and nucleus accumbens. Brain Res 1131: 88-96.
40. Sasaki T, Kotera J, Omori K (2004) Transcriptional activation of phosphodi-esterase 7B1 by dopamine D1 receptor stimulation through the cyclic AMP/ cyclic AMP-dependent protein kinase/cyclic AMP-response element binding protein pathway in primary striatal neurons. J Neurochem 89: 474-483.
41. Kuwajima M, Dehoff MH, Furuichi T, Worley PF, Hall RA, et al. (2007) Localization and expression of group I metabotropic glutamate receptors in the mouse striatum, globus pallidus, and subthalamic nucleus: regulatory effects of MPTP treatment and constitutive Homer deletion. J Neurosci 27: 6249-6260.
42. Pearson AG, Curtis MA, Waldvogel HJ, Faull RL, Dragunow M (2005). Activating transcription factor 2 expression in the adult human brain: association with both neurodegeneration and neurogenesis. Neuroscience 133: 437-451.
43. Winter C, Schenkel J, Burger E, Eickmeier C, Zimmermann M, et al. (2000) The immunophilin ligand FK506, but not GPI-1046, protects against neuronal death and inhibits c-Jun expression in the substantia nigra pars compacta following transection of the rat medial forebrain bundle. Neuroscience 95: 753-762.
44. Calabresi P, Centonze D, Bernardi G (2000) Electrophysiology of dopamine in normal and denervated striatal neurons. Trends Neurosci 23: S57-63.
45. Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, et al. (2010) Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65: 66-79.
46. Cao P, Yuan Y, Pehek EA, Moise AR, Huang Y, et al. Alpha-synuclein disrupted dopamine homeostasis leads to dopaminergic neuron degeneration in Caenorhabditis elegans. PLoS One 5: e9312.
47. Cabin DE, Shimazu K, Murphy D, Cole NB, Gottschalk W, et al. (2002) Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci 22: 8797-8807.
48. Lehmann A (1974) Atlas stereotaxique du Cerveau de la Souris Centre National de la Recherche Scientifique, Paris.
49. Seidel K, Schols L, Nuber S, Petrasch-Parwez E, Gierga K, et al. First appraisal of brain pathology owing to A30P mutant alpha-synuclein. Ann Neurol 67: 684-689.
50. Romero J, de Miguel R, Garcia-Palomero E, Fernandez-Ruiz JJ, Ramos JA (1995) Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function. Brain Res 694: 223-232.
51. Rubino T, Massi P, Patrini G, Venier I, Giagnoni G, et al. (1994) Chronic CP-55,940 alters cannabinoid receptor mRNA in the rat brain: an in situ hybridization study. Neuroreport 5: 2493-2496.
52. Lastres-Becker I, Berrendero F, Lucas JJ, Martin-Aparicio E, Yamamoto A, et al. (2002) Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease. Brain Res 929: 236-242.
53. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, et al. (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11: 563-583.
54. Grundemann J, Schlaudraff F, Haeckel O, Liss B (2008) Elevated alpha-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease. Nucleic Acids Res 36: e38.
55. Calabresi P, Gubellini P, Picconi B, Centonze D, Pisani A, et al. (2001) Inhibition of mitochondrial complex II induces a long-term potentiation of NMDA-mediated synaptic excitation in the striatum requiring endogenous dopamine. J Neurosci 21: 5110-5120.
56. Picconi B, Centonze D, Hakansson K, Bernardi G, Greengard P, et al. (2003) Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 6: 501-506.
57. Costa C, Belcastro V, Tozzi A, Di Filippo M, Tantucci M, et al. (2008) Electrophysiology and pharmacology ofstriatal neuronal dysfunction induced by mitochondrial complex I inhibition. J Neurosci 28: 8040-8052.